Wave Life Sciences Prices $100 Million Public Offering of Ordinary Shares
07 déc. 2023 07h00 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Dec. 07, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Announces Proposed Public Offering of Ordinary Shares and Pre-Funded Warrants
06 déc. 2023 16h10 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Dec. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Announces Initiation of Dosing in RestorAATion Clinical Program Evaluating First-Ever RNA Editing Candidate, WVE-006, for Alpha-1 Antitrypsin Deficiency
06 déc. 2023 16h08 HE
|
Wave Life Sciences USA, Inc.
Wave Life Sciences Announces Initiation of Dosing in Clinical Trial Evaluating First-Ever RNA Editing Candidate, WVE-006, in Alpha-1 Antitrypsin Deficiency
Wave Life Sciences to Present at 6ᵗʰ Annual Evercore ISI HealthCONx Conference
22 nov. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 22, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Reports Third Quarter 2023 Financial Results and Provides Business Update
09 nov. 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
Initiated RestorAATion clinical program for WVE-006, industry’s first-ever RNA editing clinical candidate, following approval of CTAs; dosing on track for 4Q 2023 and first-in-human proof-of-mechanism...
Wave Life Sciences Third Quarter 2023 Financial Results Scheduled for November 9, 2023
03 nov. 2023 16h05 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Nov. 03, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Highlights Growth Strategy for Building the Leading RNA Medicines Company in Annual R&D Day
28 sept. 2023 16h15 HE
|
Wave Life Sciences USA, Inc.
Presented preclinical proof-of-concept data for new, wholly owned program targeting INHBE for metabolic disorders, including obesity, which uses Wave’s best-in-class GalNAc-siRNA capabilities and...
Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
25 sept. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
06 sept. 2023 08h30 HE
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
05 sept. 2023 07h30 HE
|
Wave Life Sciences USA, Inc.
WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce...